OXER1 mediates testosterone-induced calcium responses in prostate cancer cells.


Journal

Molecular and cellular endocrinology
ISSN: 1872-8057
Titre abrégé: Mol Cell Endocrinol
Pays: Ireland
ID NLM: 7500844

Informations de publication

Date de publication:
01 01 2022
Historique:
received: 13 06 2021
revised: 23 09 2021
accepted: 06 10 2021
pubmed: 12 10 2021
medline: 31 3 2022
entrez: 11 10 2021
Statut: ppublish

Résumé

In prostate cancer, calcium homeostasis plays a significant role in the disease's development and progression. Intracellular calcium changes are an important secondary signal, triggered by a variety of extracellular stimuli, that controls many cellular functions. One of the main events affecting calcium is androgen signaling. Indeed, via calcium changes, androgens regulate cell processes like cell growth, differentiation and motility. In the present work we explored the nature of the receptor involved in calcium response induced by membrane-acting testosterone in prostate cancer cells. We report that testosterone, independently of the presence of the classical androgen receptor, can rapidly increase intracellular calcium from calcium stores, through the oxoeicosanoid receptor 1 (OXER1) and a specific signaling cascade that triggers calcium release from the endoplasmic reticulum. These findings reveal for the first time the receptor involved in the rapid calcium changes induced by androgens. Moreover, they further support the notion that androgens, even in the absence of AR, can still exert specific effects that regulate cancer cell fate.

Identifiants

pubmed: 34634385
pii: S0303-7207(21)00331-2
doi: 10.1016/j.mce.2021.111487
pii:
doi:

Substances chimiques

5-oxo-eicosatetraenoic acid 0
Arachidonic Acids 0
OXER1 protein, human 0
Receptors, Eicosanoid 0
Testosterone 3XMK78S47O
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111487

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Athanasios A Panagiotopoulos (AA)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece.

Konstantina Kalyvianaki (K)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece.

Bourcin Serifoglou (B)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece.

Evangelia Konstantinou (E)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece.

George Notas (G)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece.

Elias Castanas (E)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece. Electronic address: castanas@uoc.gr.

Marilena Kampa (M)

Laboratory of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece. Electronic address: kampam@uoc.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH